# A Randomized Study of Sulindac in Oral Premalignant Lesions

> **NCT00299195** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 63 (actual)

## Conditions studied

- Leukoplakia, Oral
- Benign Neoplasms

## Interventions

- **DRUG:** sulindac
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00299195
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02-23
- **Primary completion:** 2020-01-06
- **Final completion:** 2020-01-06
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2020-11-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00299195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00299195, "A Randomized Study of Sulindac in Oral Premalignant Lesions". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00299195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*